Antiviral therapy against Neuroinvasive West Nile virus: Nafamostat Mesilate (NM) increases the expression of RIPK3, promotes chemokines production, inhibits neuroinflammation, and restricts neuroinvasive West Nile virus production and pathogenesis in neurons via up regulation of its target gene, 11/November/2017, 10.41 pm

Natural product-based therapy for Deafness: A therapeutic mix encompassing Fenofibrate, Cholecalciferol, and DIM (FECAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes, 05/November/2017, 12.08 am
November 4, 2017
Vitamin-based PD-1 pathway activation for Pain therapy: Cholecalciferol  increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gen, 11/November/2017, 10.46  pm
November 5, 2017
Show all

Introduction: What they say

A study from the Department of Immunology, University of Washington, Seattle, WA 98109, USA; Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA 98109, USA shows that “RIPK3 Restricts Viral Pathogenesis via Cell Death-Independent Neuroinflammation.” This research paper was published, in the 30 March 2017 issue of the journal “Cell” [One of the best research journals in General biology with an I.F of 28.710], by Prof. Andrew Oberst, Brian P. Daniels and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Antiviral therapy against Neuroinvasive West Nile virus: Nafamostat Mesilate (NM) increases the expression of RIPK3, promotes chemokines production, inhibits neuroinflammation, and restricts neuroinvasive West Nile virus production and pathogenesis in neurons via up regulation of its target gene

Price 300[easy_payment currency=”USD”]


What is known?

Prof. Andrew Oberst’s research team has recently shown that mice deficient in Receptor-interacting protein kinase-3 (RIPK3): a) are highly susceptible to neuroinvasive West Nile virus (WNV); b) poorly induce chemokine expression in neurons; and c) poorly recruit T lymphocytes and inflammatory myeloid cells in central nervous system (CNS).


From Research findings to Therapeutic opportunity:

This study suggests, for the first time, a natural product-based antiviral therapy against RNA viruses such as neuroinvasive West Nile virus (WNV).

Nafamostat Mesilate (NM), by increasing the expression of its target gene, it may increase the expression of RIPK3 (Figure 1). Thereby, it may: (1) augment chemokine levels; (2) trigger neuroinflammation; (3) stall neuroinvasive West Nile virus replication; (4) promote clearance of neuroinvasive West Nile virus (WNV); and (5) strengthen antiviral immunity against RNA viruses.

Figure 1. The antidiabetic medication Nafamostat Mesilate (NM) functions as an antiviral agent. Nafamostat Mesilate (NM) inhibits neuroinvasive West Nile virus (WNV) pathogenesis via up regulation of its target gene RIPK3

Thus, pharmacological formulations encompassing “Nafamostat Mesilate (NM) or its analogues, either alone or in combination with any of the known antiviral compounds” may be used to treat infections caused by neuroinvasive West Nile virus (Figures 1-2 ).


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Nafamostat Mesilate (NM) increase the expression of Receptor-interacting protein kinase-3 (RIPK3)?

Amount: $300#

For payment and purchase details, you may reach us at admin@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Antiviral therapy against Neuroinvasive West Nile virus: Nafamostat Mesilate (NM) increases the expression of RIPK3, promotes chemokines production, inhibits neuroinflammation, and restricts neuroinvasive West Nile virus production and pathogenesis in neurons via up regulation of its target gene, 11/November/2017, 10.41 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at admin@genomediscovery.org

Comments are closed.